The clinical impact of androgen deprivation therapy on SARS-CoV-2 infection rates and disease severity
Özgür Kazan, Meftun Çulpan, Özgür Efiloğlu, Gökhan Atis, Asıf Yildirim
Türk Üroloji Dergisi/Turkish Journal of Urology, doi:10.5152/tud.2021.21278
Objective: The protective effect of androgen deprivation therapy (ADT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel hypothesis. ADT may protect patients with prostate cancer through the inhibition of androgen receptor-dependent transmembrane serine protease type 2. We analyzed the role of ADT on SARS-CoV-2 infection risk and disease severity. Material and methods: Between August 2020 and June 2021, patients with prostate cancer were included in our study. Patients were divided into two groups as men receiving ADT or not. Patients' characteristics such as prostate cancer grade and stage, comorbidities, SARS-CoV-2 infection status, and infection severity were assessed. SARS-CoV-2-infected close relatives and patients' compliance with the precautions against SARS-CoV-2 were also analyzed. Results: A total of 365 patients, 138 (37.8%) with ADT and 227 (62.2%) without ADT, were included in our analysis. Patients with ADT were older (71.8 vs 66.9 years, P ¼ .001) and had a higher rate of chronic obstructive pulmonary disease (11.6% vs 5.7%, P ¼ .044). Patients receiving ADT were more often locally advanced and metastatic (80.4% vs 32.6%, P ¼ .001). SARS-CoV-2 infection rates were statistically similar between patients who received and did not receive ADT (9.4% vs 13.2%, P ¼ .275, respectively). There was no significant difference between two groups in terms of hospitalization rates (2.9% vs 0.9%, P ¼ .205). In multivariate analysis, the presence of SARS-CoV-2-infected close relatives and precautions score were only independent predictors for both risk of SARS-CoV-2 infection and infection severity.
Conclusion: We could not find any effect of ADT on risk and severity of SARS-CoV-2 infection. SARS-CoV-2 infection and hospitalization rates were similar between patients with and without ADT.
Ethics Committee Approval: Ethical committee approval was received from the _ Istanbul Medeniyet University (2021/440). Informed Consent: Written informed consent was obtained from all participants who participated in this study. Peer-review: Externally peer-reviewed. Author
References
Asselta, Paraboschi, Mantovani, Duga, ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy, Aging,
doi:10.18632/aging.103415Bennink, Foidart, Debruyne, Treatment of serious COVID-19 with testosterone suppression and highdose estrogen therapy, Eur Urol,
doi:10.1016/j.eururo.2021.06.024Caffo, Zagonel, Baldessari, On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2, Ann Oncol,
doi:10.1016/j.annonc.2020.06.005Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Jin, Bai, He, Gender differences in patients with COVID-19: Focus on severity and mortality, Front Public Heal
Karimi, Nowroozi, Alilou, Amini, Effects of androgen deprivation therapy on COVID-19 in patients with prostate cancer: A systematic review and meta-analysis, Urol J,
doi:10.22037/uj.v18i.6691Klein, Li, Milinovich, Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2, J Urol,
doi:10.1097/JU.0000000000001338Lucas, Heinlein, Kim, The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis, Cancer Discov,
doi:10.1158/2159-8290.CD-13-1010Mikkonen, Pihlajamaa, Sahu, Zhang, Oa, Androgen receptor and androgen-dependent gene expression in lung, Mol Cell Endocrinol,
doi:10.1016/j.mce.2009.12.022Montopoli, Zumerle, Vettor, Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: A population-based study (N ¼ 4532), Ann Oncol,
doi:10.1016/j.annonc.2020.04.479Walls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell,
doi:10.1016/j.cell.2020.02.058Xu, Wang, Xiao, Nuclear receptor ERRa and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer, Oncogene,
doi:10.1038/s41388-018-0409-7
